“Adaptimmune reported Q3 financials including net loss of $1MM and a cash balance.”,” the firm’s analyst wrote.
ALIM has been the topic of a number of other research reports. HC Wainwright set a $5.00 target price on Alimera Sciences and gave the company a buy rating in a report on Tuesday, July 11th. Zacks Investment Research downgraded Alimera Sciences from a buy rating to a hold rating in a research report on Thursday, July 13th. Finally, ValuEngine raised Alimera Sciences from a strong sell rating to a sell rating in a research report on Friday, October 20th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company. The stock presently has a consensus rating of Hold and an average target price of $3.38.
Shares of Alimera Sciences (NASDAQ:ALIM) traded down $0.01 on Thursday, hitting $1.33. The stock had a trading volume of 2,440 shares, compared to its average volume of 258,346. Alimera Sciences has a 12-month low of $1.04 and a 12-month high of $1.72. The company has a current ratio of 4.63, a quick ratio of 4.51 and a debt-to-equity ratio of -0.72.
Institutional investors and hedge funds have recently modified their holdings of the stock. KCG Holdings Inc. increased its position in shares of Alimera Sciences by 127.0% during the first quarter. KCG Holdings Inc. now owns 78,604 shares of the biopharmaceutical company’s stock valued at $110,000 after acquiring an additional 43,977 shares during the last quarter. PNC Financial Services Group Inc. increased its position in Alimera Sciences by 24.3% in the second quarter. PNC Financial Services Group Inc. now owns 180,300 shares of the biopharmaceutical company’s stock worth $251,000 after buying an additional 35,200 shares during the last quarter. Finally, JW Asset Management LLC increased its position in Alimera Sciences by 15.6% in the second quarter. JW Asset Management LLC now owns 966,000 shares of the biopharmaceutical company’s stock worth $1,343,000 after buying an additional 130,000 shares during the last quarter. 37.17% of the stock is owned by institutional investors.
Alimera Sciences Company Profile
Alimera Sciences, Inc (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina.
What are top analysts saying about Alimera Sciences Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Alimera Sciences Inc. and related companies.